title: Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study.
abstract: BACKGROUND
  pre-eclampsia (PEecl) can be defined as non-severe (NS-PEecl) or severe (S-PEecl). Our study aimed to determine the incidence of antiphospholipid antibodies (aPLs) in women with a past history of NS-PEecl or S-PEecl.
  
  
  METHODS
  This case-control study includes 195 control women, 199 NS-PEecl patients and 143 S-PEecl patients whose plasma samples were collected 6 months after their first delivery. Each plasma was tested for lupus anticoagulant (LA), anticardiolipin (aCL) and antiβ2GP1 antibodies, as well as antibodies against phosphatidylserine/prothrombin complex (aPS/PT) and domain I of the β2GP1.
  
  
  RESULTS
  When compared with the control group no significant associations were found for the NS-PEecl group after adjustment of confounding variables. For the S-PEecl group, there was an association with antiβ2GP1 immunoglobulin G (IgG) (OR 16.91, 95% CI 3.71-77.06), as well as age, obesity, smoking and multiparity. Antiβ2GP1-domain I IgG was associated with aCL, antiβ2GP1 and aPS/PT IgG in the three groups. aPS/PT IgG was associated with aCL IgG, and aPS/PT IgM was associated with aCL and antiβ2GP1 IgM in the three groups.
  
  
  CONCLUSIONS
  S-PEecl is a distinct entity from NS-PEecl and is mainly associated with the presence of antiβ2GP1 IgG. Antiβ2GP1 domain I correlates with other aPL IgG tests, and aPS/PT may be promising in patients for whom LA tests cannot be interpreted.
authors.affiliation: Haemostasis Unit, University Hospitals and Faculty of Medicine of Geneva, Geneva, Switzerland.
authors.forename: T
authors.initials: T
authors.lastname: Marchetti
authors.affiliation: Haemostasis Unit, University Hospitals and Faculty of Medicine of Geneva, Geneva, Switzerland.
authors.forename: P
authors.initials: P
authors.lastname: de Moerloose
authors.affiliation: Laboratoire et Consultations d'Hématologie, CHU Nîmes, Nîmes, France.
authors.forename: J C
authors.initials: JC
authors.lastname: Gris
mesh_terms: D000328:Adult; D017152:Antibodies, Antiphospholipid / Q000097:blood*; D016736:Antiphospholipid Syndrome / Q000097:blood; D002308:Cardiolipins / Q000097:blood; D016022:Case-Control Studies; D015331:Cohort Studies; D005260:Female; D017359:HELLP Syndrome / Q000276:immunology; D006801:Humans; D006973:Hypertension / Q000150:complications; D007074:Immunoglobulin G / Q000097:blood; D016682:Lupus Coagulation Inhibitor / Q000097:blood; D008875:Middle Aged; D010718:Phosphatidylserines / Q000737:chemistry; D011225:Pre-Eclampsia / Q000097:blood* / Q000276:immunology*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000097:blood / Q000175:diagnosis; D000072417:Protein Domains; D011516:Prothrombin / Q000737:chemistry; D012306:Risk; D016896:Treatment Outcome; D053482:beta 2-Glycoprotein I / Q000737:chemistry
chemical_list: D017152:Antibodies, Antiphospholipid; D002308:Cardiolipins; D007074:Immunoglobulin G; D016682:Lupus Coagulation Inhibitor; D010718:Phosphatidylserines; D053482:beta 2-Glycoprotein I; D011516:Prothrombin
keywords: antibodies, anticardiolipin; antibodies, antiphospholipid; beta 2-Glycoprotein I; lupus anticoagulant; pre-eclampsia